Outstanding Scientific Achievement Award Lecture 2011: Defeating Diabesity
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 28 of the 28 references it cites were found in a registry or an index.
Abstract
2011 Outstanding Scientific Achievement Award.The award was presented at the Association's 71st Scientific Sessions
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These trials have more or less uniformly demonstrated a benefit, with lifestyle more efficacious than all medications with the exception of the thiazolidinediones140–152.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [141]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Boström, E. A., Choi, J. H., Long, J. Z., et al. (2012) · Nature · doi:10.1038/nature10777 · Cited by 4,810
A Potential Decline in Life Expectancy in the United States in the 21st Century
Olshansky, S. J., Passaro, D. J., Hershow, R. C., Layden, J., Carnes, B. A., Brody, J., Hayflick, L., Butler, R. N., Allison, D. B., & Ludwig, D. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmsr043743 · Cited by 2,612 · cited 1×
“Type 2 diabetes and obesity, often referred to as “diabesity,” constitute two closely linked health threats of modern societies that continue to rise in prevalence despite decades of research investment (1).”
BackgroundCirculating Ghrelin Levels Are Decreased in Human Obesity
Tschöp, M., Weyer, C., Tataranni, P. A., Devanarayan, V., Ravussin, E., & Heiman, M. L. (2001) · Diabetes · doi:10.2337/diabetes.50.4.707 · Cited by 2,008 · cited 2×
“afferent information as it typically responds most efficiently to distinct patterns rather than to changes in a single peripheral signal, for example, altered circulating concentrations of the adiposity promoting stomach hormone ghrelin (13).”
BackgroundSelf-citationThe Path to Personalized Medicine
Hamburg, M. A., & Collins, F. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006304 · Cited by 1,970
A Potential Decline in Life Expectancy in the United States in the 21st Century
Olshansky, S. J., Passaro, D. J., Hershow, R. C., Layden, J., Carnes, B. A., Brody, J., Hayflick, L., Butler, R. N., Allison, D. B., & Ludwig, D. S. (2005) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000167407.83915.e7 · Cited by 1,944
The role of neuropeptide Y in the antiobesity action of the obese gene product
Stephens, T. W., Basinski, M., Bristow, P. K., Bue-Valleskey, J. M., Burgett, S. G., Craft, L., Hale, J., Hoffmann, J., Hsiung, H. M., Kriauciunas, A., et al. (1995) · Nature · doi:10.1038/377530a0 · Cited by 1,498
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641 · cited 3×
“Numerous coagonists with differing ratios of glucagon versus GLP-1 agonism were designed and synthesized followed by extensive testing by in vitro and in vivo methods (19) (Fig.”
BackgroundMethodSelf-citationRoth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436 · cited 2×
“They demonstrated in rodents and humans that combined treatment with parallel injections of the pancreatic hormone amylin and leptin synergistically enhanced body weight loss and metabolism to an extent not possible with monotherapy (15).”
BackgroundBariatric Surgery for Morbid Obesity
DeMaria, E. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmct067019 · Cited by 427
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409 · cited 2×
“These results were independently confirmed by studies at Merck Research Laboratories working with lower potency coagonists based upon oxyntomodulin (20).”
BackgroundResultLaferrère, B., Reilly, D., Arias, S., Swerdlow, N., Gorroochurn, P., Bawa, B., Bose, M., Teixeira, J., Stevens, R. D., Wenner, B. R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002043 · Cited by 384 · cited 2×
“ghrelin, amylin, or PYY(3–36), rapidly improve from impaired levels typically associated with obesity and type 2 diabetes (14).”
BackgroundSpeakman, J. R. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.161 · Cited by 361
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure
Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., & Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci25483 · Cited by 290 · cited 2×
“Common wisdom had directed attention to the development of GIP antagonists for the treatment of diabesity based upon study with a putative GIP antagonist (21) and separate work using targeted mouse mutagenesis where the GIP receptor gene had been disrupted (22).”
BackgroundAntidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Hedbacker, K., Birsoy, K., Wysocki, R. W., Asilmaz, E., Ahima, R. S., Farooqi, I. S., & Friedman, J. M. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.11.007 · Cited by 280 · cited 2×
“As an example, it took more than a decade to appreciate the recently discovered role for leptin in control of glucose independent of body weight change, along with its potential for use in the treatment of type 1 diabetes (6).”
BackgroundNeel, J. V., Weder, A. B., & Julius, S. (1998) · Perspectives in Biology and Medicine · doi:10.1353/pbm.1998.0060 · Cited by 258 · cited 2×
“The argument is grounded in the so-called thrifty gene hypothesis, which professes that our genetic constitution was shaped to survive long periods under variable and uncertain caloric supply (25).”
BackgroundMcClean, P. L., Irwin, N., Cassidy, R. S., Holst, J. J., Gault, V. A., & Flatt, P. R. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00460.2007 · Cited by 239 · cited 2×
“Common wisdom had directed attention to the development of GIP antagonists for the treatment of diabesity based upon study with a putative GIP antagonist (21) and separate work using targeted mouse mutagenesis where the GIP receptor gene had been disrupted (22).”
BackgroundGLP-1 and energy balance: an integrated model of short-term and long-term control
Barrera, J. G., Sandoval, D. A., D'Alessio, D. A., & Seeley, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.77 · Cited by 220 · cited 2×
“The incretin hormone GLP1, which also targets CNS neurons, was chosen as one component since it has the proven capability to lower glucose and increase satiety (17).”
BackgroundMüller, T. D., Sullivan, L. M., Habegger, K., Yi, C., Kabra, D., Grant, E., Ottaway, N., Krishna, R., Holland, J., Hembree, J., et al. (2012) · Journal of Peptide Science · doi:10.1002/psc.2408 · Cited by 156
Self-citationDietary Approaches to the Treatment of Obesity
Makris, A., & Foster, G. D. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.08.004 · Cited by 154 · cited 1×
“Numerous large and wellcontrolled studies have repeatedly shown that once patients establish significant obesity, no dietary or exercise regimen can restore and sustain a healthy body weight for any reasonably prolonged period in more than a tiny fraction of afflicted patients (2).”
BackgroundCentral Nervous System Regulation of Energy Metabolism: Ghrelin versus Leptin
Nogueiras, R., Tschöp, M. H., & Zigman, J. M. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1433.054 · Cited by 115 · cited 2×
“response in the form of efferent molecular signals is returned to metabolically relevant tissues and organs to orchestrate systemic homeostasis via coregulation of behavioral and metabolic processes (12).”
BackgroundSelf-citationBayham, B. E., Greenway, F. L., Bellanger, D. E., & O'Neil, C. E. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0151 · Cited by 59 · cited 2×
“In some cases, diabetes is cured long before any significant amounts of weight loss occur (9).”
BackgroundPeptides and Their Potential Role in the Treatment of Diabetes and Obesity
Greenwood, H. C., Bloom, S. R., & Murphy, K. G. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.355 · Cited by 48 · cited 1×
“Multiple other intriguing peptides and proteins emerged as drug candidates, including glucagon-like peptide 1, amylin, adiponectin, ghrelin, resistin, glucose-dependent insulin stimulatory peptide, peptide YY(3-36) (PYY(3-36)), and oxyntomodulin (5).”
BackgroundTam, C. S., Berthoud, H. ‐., Bueter, M., Chakravarthy, M. V., Geliebter, A., Hajnal, A., Holst, J., Kaplan, L., Pories, W., Raybould, H., et al. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00902.x · Cited by 48 · cited 2×
“Once these mechanisms are identified, achieving comparably impressive body weight loss and glucose improvement not with surgery, but instead with pharmacology, becomes ever more feasible (10).”
BackgroundIn vivo assessment of the metabolic alterations in glucagonoma syndrome
Klein, S., Jahoor, F., Baba, H., Townsend, C. M., Shepherd, M., & Wolfe, R. R. (1992) · Metabolism · doi:10.1016/0026-0495(92)90005-u · Cited by 31 · cited 2×
“Will chronic glucagon agonism function equally in humans as it has in rodents, and furthermore is the preferred ratio for minimizing adverse effects common across species? One point to note in that regard is the unusually progressive wasting syndrome observed in patients suffering with glucagonomas (23).”
BackgroundMechanism of Action of Anti-ovulatory Compounds
Lunenfeld, B., Sulimovici, S., & Rabau, E. (1963) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-23-4-391 · Cited by 28 · cited 2×
“Contraceptives were developed by pharmacologically modifying one or several afferent signals in “tricking the brain to perceive pregnancy” when none existed, thereby shutting down parts of the reproductive system (27).”
BackgroundEmerging pharmacotherapy for obesity
Aronne, L. J., Powell, A. G., & Apovian, C. M. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.609168 · Cited by 26 · cited 2×
“Regulatory agencies have not approved any new drug for the treatment of obesity since 1999 (the single exception being the European approval of rimonabant, a cannabinoid receptor antagonist/inverse agonist, which was subsequently terminated due to safety concerns) (3).”
BackgroundEFFECT OF GLUCAGON ON OXYGEN CONSUMPTION IN THE COLD-ADAPTED RAT
Holloway, S. A., & Stevenson, J. A. F. (1964) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y64-096 · Cited by 4 · cited 2×
“Unopposed, chronic glucagon agonism triggers lipolysis and promotes thermogenesis (18).”
Background
Cited by
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“Ex-9 and most GIPR antagonists are in fact nonselective and function as partial agonists at their respective receptors (Tschöp and DiMarchi, 2012).”
BackgroundIslet α cells and glucagon--critical regulators of energy homeostasis
Campbell, J. E., & Drucker, D. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.51 · Cited by 266
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174
The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications
Madsbad, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12119 · Cited by 146
“Future therapeutic strategies targeting a combination of these hormones are advancing into clinical studies, which could result in a superior appetitesuppressing hormone profile and greater weight loss than single-agent therapies have provided so far [163,164].”
Background
Metadata
- Authors
- Tschöp, M. H., & DiMarchi, R. D.
- Affiliations
- Helmholtz Munich (DE)
- Indiana University Bloomington (US)
- Corresponding author
- Tschöp, Matthias H.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2012-05-14
- Volume
- 61
- Issue
- 6
- Pages
- 1309-1314
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3357302
- OpenAlex
- W2109064292
- Cited by
- 32
- References
- 27
- Citations by year
- 2023: 1 · 2020: 1 · 2019: 1 · 2017: 3 · 2016: 3 · 2015: 5 · 2014: 7 · 2013: 9 · 2012: 2
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- diabesity, obesity, obesity-related diabetes
- MeSH terms
- Awards and Prizes, Diabetes Mellitus, Type 2, Humans, Obesity, Societies, Scientific, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.